29 research outputs found
Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients.
BACKGROUND: Recent evidence suggests that immunotherapy efficacy in melanoma is modulated by gut microbiota. Few studies have examined this phenomenon in humans, and none have incorporated metatranscriptomics, important for determining expression of metagenomic functions in the microbial community.
METHODS: In melanoma patients undergoing immunotherapy, gut microbiome was characterized in pre-treatment stool using 16S rRNA gene and shotgun metagenome sequencing (n = 27). Transcriptional expression of metagenomic pathways was confirmed with metatranscriptome sequencing in a subset of 17. We examined associations of taxa and metagenomic pathways with progression-free survival (PFS) using 500 × 10-fold cross-validated elastic-net penalized Cox regression.
RESULTS: Higher microbial community richness was associated with longer PFS in 16S and shotgun data (p \u3c 0.05). Clustering based on overall microbiome composition divided patients into three groups with differing PFS; the low-risk group had 99% lower risk of progression than the high-risk group at any time during follow-up (p = 0.002). Among the species selected in regression, abundance of Bacteroides ovatus, Bacteroides dorei, Bacteroides massiliensis, Ruminococcus gnavus, and Blautia producta were related to shorter PFS, and Faecalibacterium prausnitzii, Coprococcus eutactus, Prevotella stercorea, Streptococcus sanguinis, Streptococcus anginosus, and Lachnospiraceae bacterium 3 1 46FAA to longer PFS. Metagenomic functions related to PFS that had correlated metatranscriptomic expression included risk-associated pathways of L-rhamnose degradation, guanosine nucleotide biosynthesis, and B vitamin biosynthesis.
CONCLUSIONS: This work adds to the growing evidence that gut microbiota are related to immunotherapy outcomes, and identifies, for the first time, transcriptionally expressed metagenomic pathways related to PFS. Further research is warranted on microbial therapeutic targets to improve immunotherapy outcomes
Recommended from our members
The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence.
Funder: Wellcome Trust (Wellcome); doi: https://doi.org/10.13039/100004440Brain metastases are a major cause of melanoma-related mortality and morbidity. We undertook whole-exome sequencing of 50 tumours from patients undergoing surgical resection of brain metastases presenting as the first site of visceral disease spread and validated our findings in an independent dataset of 18 patients. Brain metastases had a similar driver mutational landscape to cutaneous melanomas in TCGA. However, KRAS was the most significantly enriched driver gene, with 4/50 (8%) of brain metastases harbouring non-synonymous mutations. Hotspot KRAS mutations were mutually exclusive from BRAFV600, NRAS and HRAS mutations and were associated with a reduced overall survival from the resection of brain metastases (HR 10.01, p = 0.001). Mutations in KRAS were clonal and concordant with extracranial disease, suggesting that these mutations are likely present within the primary. Our analyses suggest that KRAS mutations could help identify patients with primary melanoma at higher risk of brain metastases who may benefit from more intensive, protracted surveillance
Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.
BACKGROUND: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. FINDINGS: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. FUNDING: UK National Institute for Health Research Health Technology Assessment
Fibrinogen Motif Discriminates Platelet and Cell Capture in Peptide-Modified Gold Micropore Arrays
Human blood platelets
and SK-N-AS neuroblastoma cancer-cell capture
at spontaneously adsorbed monolayers of fibrinogen-binding motifs,
GRGDS (generic integrin adhesion), HHLGGAKQAGDV (exclusive to platelet
integrin α<sub>IIb</sub>β<sub>3</sub>), or octanethiol
(adhesion inhibitor) at planar gold and ordered 1.6 μm diameter
spherical cap gold cavity arrays were compared. In all cases, arginine/glycine/aspartic
acid (RGD) promoted capture, whereas alkanethiol monolayers inhibited
adhesion. Conversely only platelets adhered to alanine/glycine/aspartic
acid (AGD)-modified surfaces, indicating that the AGD motif is recognized
preferentially by the platelet-specific integrin, α<sub>IIb</sub>β<sub>3</sub>. Microstructuring of the surface effectively
eliminated nonspecific platelet/cell adsorption and dramatically enhanced
capture compared to RGD/AGD-modified planar surfaces. In all cases,
adhesion was reversible. Platelets and cells underwent morphological
change on capture, the extent of which depended on the topography
of the underlying substrate. This work demonstrates that both the
nature of the modified interface and its underlying topography influence
the capture of cancer cells and platelets. These insights may be useful
in developing cell-based cancer diagnostics as well as in identifying
strategies for the disruption of platelet cloaks around circulating
tumor cells
Peptide-Mediated Platelet Capture at Gold Micropore Arrays
Ordered
spherical cap gold cavity arrays with 5.4, 1.6, and 0.98 μm
diameter apertures were explored as capture surfaces for human blood
platelets to investigate the impact of surface geometry and chemical
modification on platelet capture efficiency and their potential as
platforms for surface enhanced Raman spectroscopy of single platelets.
The substrates were chemically modified with single-constituent self-assembled
monolayers (SAM) or mixed SAMs comprised of thiol-functionalized arginine–glycine–aspartic
acid (RGD, a platelet integrin target) with or without 1-octanethiol
(adhesion inhibitor). As expected, platelet adhesion was promoted
and inhibited at RGD and alkanethiol modified surfaces, respectively.
Platelet adhesion was reversible, and binding efficiency at the peptide
modified substrates correlated inversely with pore diameter. Captured
platelets underwent morphological change on capture, the extent of
which depended on the topology of the underlying substrate. Regioselective
capture of the platelets enabled study for the first time of the surface
enhanced Raman spectroscopy of single blood platelets, yielding high
quality Raman spectroscopy of individual platelets at 1.6 μm
diameter pore arrays. Given the medical importance of blood platelets
across a range of diseases from cancer to psychiatric illness, such
approaches to platelet capture may provide a useful route to Raman
spectroscopy for platelet related diagnostics
Association of increased somatic mutations in metastatic melanoma patients with clinical outcome.
Prediction of response and toxicity to immune checkpoint inhibitor therapies (ICI) in melanoma using deep neural networks machine learning.
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
Abstract Background Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patients with high-risk resected melanoma. We herein report on the pooled long-term survival outcomes of these patients in comparison to historical controls. Methods All melanoma patients treated at NYU Langone Health under any of three prospective adjuvant NY-ESO-1 vaccine trials were retrospectively pooled into a single cohort. All such patients with stage III melanoma were subsequently compared to historical control patients identified via a prospective institutional database with protocol-driven follow-up. Survival times were calculated using the Kaplan-Meier method, and Cox proportional hazard models were employed to identify significant prognostic factors and control for confounding variables. Results A total of 91 patients were treated with an NY-ESO-1 vaccine for the treatment of high-risk resected melanoma. Of this group, 67 patients were stage III and were selected for comparative analysis with 123 historical control patients with resected stage III melanoma who received no adjuvant therapy. Among the pooled vaccine cohort (median follow-up 61 months), the estimated median recurrence-free survival was 45 months, while the median overall survival was not yet reached. In the control cohort of 123 patients (median follow-up 30 months), the estimated median recurrence-free and overall survival were 22 and 58 months, respectively. Within the retrospective stage III cohort, NY-ESO-1 vaccine was associated with decreased risk of recurrence (HR = 0.56, p < 0.01) and death (HR = 0.51, p = 0.01). Upon controlling for sub-stage, the adjuvant NY-ESO-1 clinical trial cohort continued to exhibit decreased risk of recurrence (HR = 0.45, p < 0.01) and death (HR = 0.40, p < 0.01). Conclusions In this small retrospective cohort of resected stage III melanoma patients, adjuvant NY-ESO-1 vaccine immunotherapy was associated with longer recurrence-free and overall survival relative to historical controls. These data support the continued investigation of adjuvant NY-ESO-1 based immunotherapy regimens in melanoma